Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction

Sang Yeob Lim, Eun Hui Bae, Joon Seok Choi, Chang Seong Kim, Jeong Woo Park, Seong Kwon Ma, Myung Ho Jeong, Soo Wan Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) reduce major adverse cardiac events (MACE) and mortality in patients with acute coronary syndrome. We investigated the effectiveness of statin therapy in reducing MACE in patients with acute myocardial infarction (AMI) and renal dysfunction (RD). In the present retrospective study of 12,853 patients with AMI, the patients were categorized into 4 groups: group I, statin therapy and no RD (estimated glomerular filtration rate <60 ml/min/1.73 m 2); group II, neither statin therapy nor RD; group III, statin therapy and RD; group IV, no statin therapy but RD. The primary end points were death and complications during the hospital course. The secondary end points were MACE during 1 year of follow-up after AMI. Significant differences in the composite MACE during 12 months of follow-up were observed among the 4 groups (group I, 11.7%; group II, 19.0%; group III, 26.7%; and group IV, 45.5%; p <0.001). In a Cox proportional hazards model, mortality at 12 months increased stepwise from group II to IV compared to group I. Moreover, MACE-free survival in the severe RD group (estimated glomerular filtration rate <30 mL/min/1.73 m 2) was also greater in the statin-treated group. In conclusion, statin therapy reduced MACE at 1 year of follow-up in patients with AMI regardless of RD.

Original languageEnglish
Pages (from-to)1425-1430
Number of pages6
JournalAmerican Journal of Cardiology
Volume109
Issue number10
DOIs
Publication statusPublished - 2012 May 15

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Myocardial Infarction
Kidney
Therapeutics
Glomerular Filtration Rate
Mortality
Acute Coronary Syndrome
Proportional Hazards Models
Disease-Free Survival
Oxidoreductases
Retrospective Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction. / Lim, Sang Yeob; Bae, Eun Hui; Choi, Joon Seok; Kim, Chang Seong; Park, Jeong Woo; Ma, Seong Kwon; Jeong, Myung Ho; Kim, Soo Wan.

In: American Journal of Cardiology, Vol. 109, No. 10, 15.05.2012, p. 1425-1430.

Research output: Contribution to journalArticle

Lim, Sang Yeob ; Bae, Eun Hui ; Choi, Joon Seok ; Kim, Chang Seong ; Park, Jeong Woo ; Ma, Seong Kwon ; Jeong, Myung Ho ; Kim, Soo Wan. / Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction. In: American Journal of Cardiology. 2012 ; Vol. 109, No. 10. pp. 1425-1430.
@article{65e1bd4d02fb4cdda87b5c9f304e247b,
title = "Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction",
abstract = "The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) reduce major adverse cardiac events (MACE) and mortality in patients with acute coronary syndrome. We investigated the effectiveness of statin therapy in reducing MACE in patients with acute myocardial infarction (AMI) and renal dysfunction (RD). In the present retrospective study of 12,853 patients with AMI, the patients were categorized into 4 groups: group I, statin therapy and no RD (estimated glomerular filtration rate <60 ml/min/1.73 m 2); group II, neither statin therapy nor RD; group III, statin therapy and RD; group IV, no statin therapy but RD. The primary end points were death and complications during the hospital course. The secondary end points were MACE during 1 year of follow-up after AMI. Significant differences in the composite MACE during 12 months of follow-up were observed among the 4 groups (group I, 11.7{\%}; group II, 19.0{\%}; group III, 26.7{\%}; and group IV, 45.5{\%}; p <0.001). In a Cox proportional hazards model, mortality at 12 months increased stepwise from group II to IV compared to group I. Moreover, MACE-free survival in the severe RD group (estimated glomerular filtration rate <30 mL/min/1.73 m 2) was also greater in the statin-treated group. In conclusion, statin therapy reduced MACE at 1 year of follow-up in patients with AMI regardless of RD.",
author = "Lim, {Sang Yeob} and Bae, {Eun Hui} and Choi, {Joon Seok} and Kim, {Chang Seong} and Park, {Jeong Woo} and Ma, {Seong Kwon} and Jeong, {Myung Ho} and Kim, {Soo Wan}",
year = "2012",
month = "5",
day = "15",
doi = "10.1016/j.amjcard.2012.01.351",
language = "English",
volume = "109",
pages = "1425--1430",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction

AU - Lim, Sang Yeob

AU - Bae, Eun Hui

AU - Choi, Joon Seok

AU - Kim, Chang Seong

AU - Park, Jeong Woo

AU - Ma, Seong Kwon

AU - Jeong, Myung Ho

AU - Kim, Soo Wan

PY - 2012/5/15

Y1 - 2012/5/15

N2 - The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) reduce major adverse cardiac events (MACE) and mortality in patients with acute coronary syndrome. We investigated the effectiveness of statin therapy in reducing MACE in patients with acute myocardial infarction (AMI) and renal dysfunction (RD). In the present retrospective study of 12,853 patients with AMI, the patients were categorized into 4 groups: group I, statin therapy and no RD (estimated glomerular filtration rate <60 ml/min/1.73 m 2); group II, neither statin therapy nor RD; group III, statin therapy and RD; group IV, no statin therapy but RD. The primary end points were death and complications during the hospital course. The secondary end points were MACE during 1 year of follow-up after AMI. Significant differences in the composite MACE during 12 months of follow-up were observed among the 4 groups (group I, 11.7%; group II, 19.0%; group III, 26.7%; and group IV, 45.5%; p <0.001). In a Cox proportional hazards model, mortality at 12 months increased stepwise from group II to IV compared to group I. Moreover, MACE-free survival in the severe RD group (estimated glomerular filtration rate <30 mL/min/1.73 m 2) was also greater in the statin-treated group. In conclusion, statin therapy reduced MACE at 1 year of follow-up in patients with AMI regardless of RD.

AB - The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) reduce major adverse cardiac events (MACE) and mortality in patients with acute coronary syndrome. We investigated the effectiveness of statin therapy in reducing MACE in patients with acute myocardial infarction (AMI) and renal dysfunction (RD). In the present retrospective study of 12,853 patients with AMI, the patients were categorized into 4 groups: group I, statin therapy and no RD (estimated glomerular filtration rate <60 ml/min/1.73 m 2); group II, neither statin therapy nor RD; group III, statin therapy and RD; group IV, no statin therapy but RD. The primary end points were death and complications during the hospital course. The secondary end points were MACE during 1 year of follow-up after AMI. Significant differences in the composite MACE during 12 months of follow-up were observed among the 4 groups (group I, 11.7%; group II, 19.0%; group III, 26.7%; and group IV, 45.5%; p <0.001). In a Cox proportional hazards model, mortality at 12 months increased stepwise from group II to IV compared to group I. Moreover, MACE-free survival in the severe RD group (estimated glomerular filtration rate <30 mL/min/1.73 m 2) was also greater in the statin-treated group. In conclusion, statin therapy reduced MACE at 1 year of follow-up in patients with AMI regardless of RD.

UR - http://www.scopus.com/inward/record.url?scp=84862777010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862777010&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2012.01.351

DO - 10.1016/j.amjcard.2012.01.351

M3 - Article

VL - 109

SP - 1425

EP - 1430

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -